LIDDS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1595 SEK | +2.90% |
|
-6.18% | +47.69% |
| Mar. 21 | Sweden's Lidds Finalizes Purchase of Noviga Research | MT |
| Mar. 21 | LIDDS AB (OM:LIDDS) completed the acquisition of Noviga Research AB. | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Lidds AB (LIDDS) is a Sweden-based company engaged in the development of pharmaceutical products. LIDDS (Local Intelligent Drug Delivery System) uses its drug delivery technology, a parenteral, microparticulate drug carrier matrix, which is administered as a paste that spreads in the tissue and ultimately cures shortly after injection, allowing local treatment at site of disease. It targets primarily solid tumors. The Companyâs portfolio includes Liproca Depot, aimed at prostate cancer with possible applications in benign prostate hypertrophy (BPH). The Liproca Depot is a bioresorbable, biocompatible and locally injectable modified release formulation of 2-hydroxyflutamid, prepared as a paste prior to injection.
Calendar
2024-05-14
- Annual General Meeting
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +47.69% | 993K | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- LIDDS Stock
- News LIDDS AB
- Sweden's Lidds Finalizes Purchase of Noviga Research
